Key Takeaways
- Mangoceuticals (NASDAQ: MGRX) has reported breakthrough field trial results for its patented compound MGX-0024, achieving 100% survival from respiratory diseases in poultry.
- Field trials in Tamil Nadu, India showed MGX-0024 significantly reduced mortality compared to untreated control farms.
- The compound, a natural polyphenol-zinc blend, aligns with global bans on antibiotic growth promoters.
- Mangoceuticals is scaling production and engaging regulators in the US, UK, Canada, and Australia.
- Additional studies and federal funding applications are underway to support international deployment and commercialization.
Mangoceuticals Announces Promising Results for MGX-0024 in Poultry Health Trials
Mangoceuticals, Inc. (NASDAQ: MGRX), a health and wellness company known for its MangoRx and PeachesRx brands, has shared compelling data from field trials of its patented antiviral blend, MGX-0024, conducted in partnership with Solice International at Duraiswamy Farm in Tamil Nadu, India.
The studies focused on combating respiratory diseases in chickens, including Newcastle Disease and Chronic Respiratory Disease (CRD), with MGX-0024 delivered through drinking water. Notably, the second trial involving 10,000 chicks from day seven recorded zero respiratory disease-related deaths.
MGX-0024 Shows High Efficacy in Comparative Field Trials
Mortality Drastically Reduced Compared to Control Groups
In the first study, 8,000 chickens treated from day 25 experienced a reduction in daily deaths from 200 (in a neighboring untreated farm) to approximately 50. Some losses were attributed to chicks arriving already infected.
In a second, more controlled trial, 10,000 chicks treated from day 7 for 48 days with no other antivirals or antibiotics had no respiratory disease-related mortality. Only 20 deaths were recorded due to heat exposure, compared to an expected 50% loss (5,000 birds) at a control farm nearby.
MGX-0024, composed of natural polyphenols and zinc (both GRAS-certified), is also being evaluated in a laboratory study for H5N1 avian influenza by Vipragen Biosciences and an Indian government lab, with results expected soon.
Mangoceuticals Positions MGX-0024 as Drug- and Vaccine-Free Alternative
Supports Global Shift Away from Antibiotic Growth Promoters
MGX-0024’s field performance aligns with growing global restrictions on antibiotics in poultry:
- India: Antibiotic growth promoter ban effective April 2025
- EU: Ban in place since 2022
- US: Ban implemented in 2017
Jacob Cohen, Co-Founder and CEO of Mangoceuticals, said: “We believe that MGX-0024 is a safe, non-toxic, all natural, easy-to-use solution that could revolutionize poultry farming by keeping flocks healthy without the use of drugs or vaccines.”
The company, together with partner IntraMont, is advancing production scale-up and initiating pilot programs with large farms in the US, UK, Canada, and Australia.
Mangoceuticals Pursues Regulatory Pathways and Federal Funding
To support international commercialization, MangoRx IP Holdings, LLC, a wholly owned subsidiary of Mangoceuticals, is securing a Commercial and Government Entity (CAGE) code. This will allow the company to pursue funding from agencies such as:
- USDA’s Agriculture and Food Research Initiative
- BARDA (Biomedical Advanced Research and Development Authority)
These programs aim to foster innovation in antibiotic alternatives and bolster preparedness for zoonotic threats like avian flu.
Jacob Cohen added: “MGX-0024 has been shown in studies to stabilize farm production and we believe this opens doors to new markets by meeting consumer and trade demands for antibiotic-free poultry.”
Next Steps for Mangoceuticals and MGX-0024
Mangoceuticals plans to conduct further field validation across multiple Indian states with H5N1 presence and expand regulatory engagement. Mangoceuticals anticipates that MGX-0024 could become a global standard in poultry health—offering a vaccine- and antibiotic-free solution that aligns with market demands for sustainable livestock farming.
